亚盛医药-B：截至2025年6月30日止六个月未经审核中期业绩公告

ASCENTAGE PHARMA GROUP INTERNATIONAL 6855 2025630 20256302024630 2025630233.732.62024630590.080.771.6%2024630678.495.3®2024630112.915.5104.514.993%2025217.430.3 20256302024145.321.523.4%766.0106.984.512.719.0%2025630528.673.848.26.953.7%2025630137.819.2®® 2025630590.882.52024630162.822.4 20256301,661.5231.9202412311,261.2172.8400.259.131.7%20251132.52025720251,492.5190.1 ®(CLL/SLL) 1.2025710®(NMPA)(BTK)(CLL/SLL) 2.®®CLL/SLLBcl-2Bcl-2 ® 1.2025630®2024630112.915.593%217.430.3 2.20251®(NRDL)3.2025630®DTP782202463017%®202463020147%2025630295 ®(CML)(ALL)®(CLL)(SLL)(AML)(MDS)(MM)(Frost & Sullivan)20351,600 ®BCR-ABL1(TKI)T315ICMLBCR-ABL1 TKIT315I(CML)(-CP)(-AP)TKICML-CP®20251®®CMLFDAIII(POLARIS-2)Ph+ ALL(SDH)(GIST)III20246Takeda Pharmaceuticals International AG®® ®Bcl-22025710(NMPA)(BTK)(CLL/SLL)®CLL/SLLBcl-2Bcl-2®III(1)®BTKBTKCLL/SLL12GLORA(2)CLL/SLLGLORA-2(3)(AZA)(AML)GLORA-3(4)AZA(HR MDS)GLORA-4 Bcl-2Bcl-2/Bcl-xL IAPMDM2-p53BCR-ABL1ALKFAKEED(PROTACs) 202563047820342 Dana-FarberMD 62025731 1.FDA 2.3.BTK(CLL/SLL)4.CLL/SLLAMLMDSMM25.NSCLC2 ® ®(TKI)®T315ICML-CPCML-APBCR-ABL1(TKI)CML-CP®20251® ®2024(NCCN) CML(CSCO) CMLPh+ ALL®FDACML(ALL)(AML)GIST(ODD)(FTD)TKICML®EMA ® 1.FDA ® 1.2025630®93%217.430.32024630112.915.5 2.20251® 3.2025630DTP782202463017%®202463047% 4.20254®CSCOCSCO 1.P O L A R I S - 1P h + A L LI I I(POLARIS-1)2.CML-CPT315IFDAIII(POLARIS-2)3.(SDH)(GIST)III(POLARIS-3)4.20253(NMPA)(CDE)(BTD)(Ph+ALL) 1.20256®2025(EHA2025)Ph+ALLPh+ALLFGFR1®(CR)(CMR)+VPPh+ ALL 2.202542025(AACR 2025)AMLT-ALL ® 1.FDA(Ph+ALL)III ® ®Bcl-2Bcl-220257®(NMPA)BTK(CLL/SLL)®CLL/SLLBcl-2Bcl-2®(CLL/SLL)(NHL)(AML)(MM)MDS(WM)®FDA(ODD)(FL)(WM)(CLL)(MM)AML ® 1.FDA 2.BTK(CLL/SLL) ® 1.2 0 2 571 0®(NMPA)BTK(CLL/SLL)®CLL/SLLBcl-2Bcl-2® 2.20254®CSCO(R/R)CLL/SLL 1.A Z A( H R )( M D S )I I I(GLORA-4)GLORA-4FDAEMA2.A Z A( A M L )I I I(GLORA-3)3.(BTK)CLL/SLLIII(GLORA-2)4.B T KBTKCLL/SLLFDAIII(GLORA)5.(MM)Ib/II6.AML/MDSIb/II7.AML/MDSIb/II8.BTKWMIb/II 1.20256®AZA(TN)(VEN)61(ASCO)Ib/II20254103R/R AMLMDSR/R AML(MPAL)(ORR)31.8%ASCO ® 1. APG-2449 APG-2449(FAK)(ALK)C-ros1(ROS1)(TKI)CDEFAKPKAPG-2449APG-2449ALK TKINSCLCAPG-2449ALK TKINSCLCFAK(pFAK)APG-2449PFSpFAKALK TKI APG-2449 1.(CDE)IIIAPG-2449(ALK) TKI(NSCLC)ALKNSCLC 2.APG-2449Ib/II 1.20254AACR 2025APG-2449FAK(SCLC) 18A.05APG-2449 Alrizomadlin (APG-115) Alrizomadlin(APG-115)MDM2-p53MDM2p53p53alrizomadlin(APG-115) AlrizomadlinFDA(ODD)A M LI I B - I VAlrizomadlinFDA(RPDD) alrizomadlin alrizomadlin 1.alrizomadlinIb/II2.alrizomadlinT(R/R T-PLL)(NHL)IIa3.alrizomadlinIICDEalrizomadlin 1.alrizomadlinPD-1(JS001(LPS)Ib/II2.alrizomadlinAMLMDSIb3.alrizomadlinI 1.2025661(ASCO)alrizomadlinPD-1(ACC)II 1 8 A . 0 5A L R I Z O M A D L I N(APG-115) Pelcitoclax (APG-1252) PelcitoclaxBcl-2Bcl-xL(SCLC)(NSCLC)(NHL)APG-1252FDA(ODD)SCLC pelcitoclaxPelcitoclax pelcitoclax Pelcitoclax 1.pelcitoclax(EGFR)NSCLCIb2.pelcitoclax(R/R NHL)Ib/II3.pelcitolclaxcobimetinibI 18A.05PELCITOCLAX (APG-1252) APG-5918 APG-5918(EED)EED2 (PRC2)APG-5918(CKD)(Hb) (FDA)IAPG-5918 APG-5918 1.APG-5918I 2.APG-5918I(SAD)(MAD) 1.20256EHA2025APG-5918APG-5918T(TCL) 2.20254AACR 2025APG-5918APG-5918PCa 18A.05APG-5918 (PK/PD) (TPD)p53-MDM220MDM2p53alrizomadlin(APG-115)p53MDM2MDM2 Bcl-xLBcl-xLBcl-xLBcl-xLBcl-xL (SAB)SABSAB 20242025630444.1528.6 2025630478202025630342 20252025®20257®20257311401,000®®®CLL/SLLBcl-2 2025630®217.42024630112.9104.593%2025TKIs(CML-CP)® (HK.1801)8672902025630DTP782202463017%®202463020147%2025630295 2025(CACA)2025CSCO(CML)(Ph+ ALL)20254BCR-ABL1T315I(Ph+ALL)2025CSCO®2024(NCCN) CML2025 ®2025710NMPA®®CDE15® ®2025CSCOCLL/SLL®CSCOCSCOBcl-2 20212022 200,0002.52022A2024ABCGMP 20234(Qualified Person, QP)GMPQPGMP 2023®®GMPFDA 2025®(CDMO)®NDA 50,000 2024614®®®11212%~19%202472 ® 2024620202461424.098503.0854924,307,32275585.7719.2625.12%20256202025123180 20246142024621202474 202512817.257,325,00029,300,000126.4983.8202521317.25935,1443,740,57616.13125.64AAPG 8,260,14433,040,576315,226,005348,266,581142.51,109.410.077.7132.51,031.8 20241229202512120251242025222025213 2025 202572568.6022,000,0001,492.517.85190.1 2025 (i)40% (ii)35% (iii)25% 20257152025725 20252024 5233,699823,746(21,650)(15,059) 8(5,512)(69) (590,824)162,826 20256 30 20252024 (590,824)162,826 (2,035)2,229 (940)2,269 (591,764)165,095 (56)(175) (591,764)165,095 669,418307,551 675,909274,162 675,909274,162 20256 30 1. 20171117Walkers Corporate Limited190 Elgin Avenue, George Town, GrandCayman KY1-9008, Cayman Islands 2. 20256303420241231 3. 20241231 21 21 4. (HBV) (a) 10% 5. 7. 8. 16.5%20242025630 20081125% (Suzhou Yasheng Pharma Co.,Ltd.)2022202315% 10% 2024202563021% 2017(Tax Cuts and Jobs Act of 2017)TCJA174202211TCJA 9. 20256302024630 20256302024630 10. 2025630341,591,0272024630291,752,282 20252024 2025630 11. 202511 2025630 202411 2024630 20256302024630 12. 13. 14. 202518,260,144ADS17.2525,000 20256300.01422,447300 202562